<DOC>
	<DOCNO>NCT00253331</DOCNO>
	<brief_summary>The purpose study determine , comparison placebo control , response two dosage strength topical gel formulation nitroglycerin , MQX-303 , determination finger blood flow skin temperature finger patient moderate severe Raynaud 's phenomenon , follwoing exposure cold temperature . Blood flow determine scan laser Doppler equipment skin temperature measure use attach thermistor probe . Following baseline measurement , study gel apply , hand place cold chamber , blood flow skin temperature monitor next two hour . Each patient receive multiple dos different day serve his/her control interpret response .</brief_summary>
	<brief_title>Lab Study MQX-503 Treatment Raynaud 's</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Nitroglycerin</mesh_term>
	<criteria>clinical diagnosis Raynaud 's phenomenon outpoatients agree apply gel per protocol willing discontinue current vasodilator therapy agree stop investigational medication Raynaud 's negative pregnancy test fertile female able give write informed consent comply study requirement current use ay nitrate medication medication interact nitroglycerin patient know allergy nitroglycerin topical gel ingredient patient history migraine headache patient unstable medical problem patient cognitive language difficulty patient screen lab value 20 % outside normal patient open lesion site application woman childbearing potential unwilling comply contraceptive requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Raynaud 's</keyword>
	<keyword>sclerderma</keyword>
	<keyword>systemic sclerosis</keyword>
	<keyword>autoimmune disease</keyword>
</DOC>